- Home
- PCRX vs AUTL Comparison
PCRX vs AUTL Comparison
Compare PCRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCRX | AUTL |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 431.2M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PCRX | AUTL |
|---|---|---|
| Price | $23.15 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $37.20 | $8.50 |
| AVG Volume (30 Days) | 797.3K | ★ 1.4M |
| Earning Date | 05-07-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 28.33 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | $10,120,000.00 |
| Revenue This Year | $7.10 | $669.62 |
| Revenue Next Year | $9.15 | $79.78 |
| P/E Ratio | $145.63 | ★ N/A |
| Revenue Growth | 26.04 | ★ 496.00 |
| 52 Week Low | $18.80 | $1.11 |
| 52 Week High | $27.99 | $2.70 |
Technical Indicators
Market Signals| Indicator | PCRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 32.11 |
| Support Level | $22.57 | N/A |
| Resistance Level | $23.91 | $1.52 |
| Average True Range (ATR) | 0.85 | 0.07 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 64.63 | 10.13 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.